KBP Biosciences, which is developing drugs for disease areas of unmet need, raised the series A funds from investors including Ping An Ventures.
US-based biopharmaceutical developer KBP Biosciences closed a $76m series A round backed by Ping An Ventures, a corporate venturing subsidiary of insurance group Ping An, on Friday.
The round was co-led by venture capital firm Advantech Capital and Chinese government-owned investment firm State Development & Investment Corporation, which invested through its SDIC Venture Capital unit.
Cash Capital, the investment arm of Chinese Academy of Sciences, also took part in the round, as did Sangel Capital Management, Bay City Capital GF…
